Cosmos Health Launches C-ScrubVet in UK, Tapping $69B Animal Health Market
COSM sits 70% above its 52-week low of $0.162.
Summary
Cosmos Health has begun commercializing its veterinary antimicrobial line, C-ScrubVet, with first orders received in the UK. The product leverages existing C-Scrub formulation and in-house EU GMP manufacturing, targeting the $69B global animal health market. The company plans to expand to additional European markets in Q4 2026, initially via e-commerce before retail and clinical channels. This launch adds a new growth channel alongside the core pharmaceutical and nutraceutical business, which reported record FY2025 revenue of $65.27M. The move aligns with previously issued 2029 guidance of $200.6M revenue, though near-term financial impact is likely modest given the early stage.
At the time of this announcement, COSM was trading at $0.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.7M. The 52-week trading range was $0.16 to $1.32. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.